P-221 Prediction of colon cancer recurrence based on proteomic biomarkers

Colorectal cancer (CRC) is the third most common and second leading cause of cancer-related death worldwide. The current standard care for nonmetastatic colon (CC) surgery followed by adjuvant treatment when a stage III or high-risk II CC diagnosed. Although 80% patients with 60% are cured alone, some them would benefit treatment. detection predictive biomarkers important to select in recurrence guide decision aim this study find useful biomarker detect I-III high risk use differential proteomic. A total 73 tumor samples from completely resected were included study. Patients stratified into two groups: Group (disease free after 5 years follow-up) B (patients who have relapsed). We perform quantitative proteomic large-scale LC-MS/MS-based assay using label techniques as SWATH-MS obtain profiling identify effective protein networks predict these patients. interesting proteins based on p-value 1.5. also analysed main clinical molecular characteristics. 25 group 48 B. median age was 68,12 (8,8; 44-85) 70,27 (8,5; 48-89) 52% 60,4% men. 48% CC, while 51,7% 41,7% at diagnostic. Only 2 I both 87,5% had histopathological negative prognostic factor vs 68% A. NRAS gene mutated 6,3% B, no mutations Loss CDX2 immunohistochemical expression detected 10,4 % tumors 4% showed that 4 significally overexpressed tumors: integrin beta-1, fibrillin-1, cacyclin binding prolargin. overexpression relapse suggests possible role biomarkers. Prolargin showing very levels only patients, having autoimmune diseases can justify findings. More studies needed validate